Piper Sandler Lowers Illumina (NASDAQ:ILMN) Price Target to $300.00

Illumina (NASDAQ:ILMNGet Rating) had its price objective decreased by Piper Sandler from $320.00 to $300.00 in a research note issued on Monday, The Fly reports. The brokerage currently has an “overweight” rating on the life sciences company’s stock. Piper Sandler’s target price indicates a potential upside of 25.79% from the stock’s current price.

ILMN has been the topic of a number of other research reports. Barclays raised their price target on Illumina from $130.00 to $175.00 and gave the stock an “underweight” rating in a research note on Friday, September 30th. Argus decreased their target price on shares of Illumina from $300.00 to $250.00 in a research report on Tuesday, October 11th. Stifel Nicolaus decreased their price objective on shares of Illumina from $480.00 to $300.00 and set a “buy” rating for the company in a research note on Friday, August 12th. Atlantic Securities cut their price objective on shares of Illumina to $190.00 in a report on Monday, August 15th. Finally, Cowen upped their price target on Illumina from $327.00 to $350.00 in a research report on Friday, November 4th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average target price of $254.38.

Illumina Trading Up 1.7 %

Shares of ILMN stock opened at $238.49 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.93 and a quick ratio of 0.72. The company has a 50-day moving average of $210.16 and a two-hundred day moving average of $213.45. Illumina has a 1-year low of $173.45 and a 1-year high of $428.00. The firm has a market cap of $37.51 billion, a PE ratio of -9.03 and a beta of 1.17.

Insider Transactions at Illumina

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $216.59, for a total transaction of $108,295.00. Following the sale, the senior vice president now owns 41,333 shares of the company’s stock, valued at $8,952,314.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Illumina

Several institutional investors have recently made changes to their positions in ILMN. Tcwp LLC acquired a new stake in shares of Illumina in the 1st quarter worth about $31,000. WASHINGTON TRUST Co acquired a new stake in shares of Illumina in the 1st quarter worth about $35,000. Brown Brothers Harriman & Co. raised its holdings in shares of Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock worth $45,000 after acquiring an additional 106 shares during the last quarter. Benjamin Edwards Inc. raised its holdings in shares of Illumina by 13,300.0% in the 1st quarter. Benjamin Edwards Inc. now owns 134 shares of the life sciences company’s stock worth $47,000 after acquiring an additional 133 shares during the last quarter. Finally, Private Trust Co. NA acquired a new stake in shares of Illumina in the 2nd quarter worth about $25,000. Institutional investors and hedge funds own 86.12% of the company’s stock.

Illumina Company Profile

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Further Reading

The Fly logo

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.